The Cutaneous Connection

James Song, MD, FAAD, chief medical officer and director of clinical research at Frontier Dermatology in Seattle, Washington, delves into the complexities and advancements in treating atopic dermatitis (AD). Song highlights the challenges of transitioning patients from topical to systemic therapies, emphasizing the need for timely conversations and patient comfort. He discusses the efficacy and rapid response of oral JAK inhibitors compared to biologics, while addressing safety concerns and the necessity for blood monitoring. Song also explores patient-specific factors in treatment choices, the importance of systemic therapy for moderate to severe cases, and the promise of emerging biologics targeting IL-31 and OX40 pathways. This episode is a comprehensive guide for dermatology clinicians navigating the evolving landscape of AD treatments.

Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.

Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut and Dermatology Times Editorial Advisory Board Member, caught up with us at the 2024 American Academy of Dermatology Meeting to decode new atopic dermatitis treatment data and how that translates to personalized options for patients.

Nanette Silverberg, MD, clinical professor of pediatrics and dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York, recently led the annual Revolutionizing Vitiligo (ReV) Virtual Conference. Discover what you need to say to overcome insurance coverage hangups with ruxolitinib, the importance of early intervention, and gain an overview of topical guidelines for patients of all ages with vitiligo.

In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management. Dr. Ruchi Gupta will lead a session on this topic at the 2023 American College of Allergy, Asthma, & Immunology Meeting in Anaheim, California.

Marty Makary, MD, MPH, FACS, is a professor at the Johns Hopkins University School of Medicine and Carey Business School, a member of the National Academy of Medicine, and a public health and public policy researcher. Makary is also a New York Times best-selling author of “Unaccountable: What Hospitals Won't Tell You and How Transparency Can Revolutionize Health Care,” and “The Price We Pay: What Broke American Health Care - And How to Fix it.” In this episode, Makary discusses the role of physician-led legislative advocacy in health care and dermatology, a topic he recently discussed in the keynote speech at the 2023 AADA Legislative Conference in Washington, DC, earlier this month.

In this episode, Jonathan Silverberg, MD, PhD, MPH, discusses of the effects of environmental pollutants on atopic dermatitis, including flares, severity, and recommendations for avoiding these pollutants when possible.